Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

Conclusions
Primary efficacy endpoints were not significantly different from placebo, although there was evidence of a minor treatment effect. No new safety signals were observed for tofacitinib.

Trial registration numbers
NCT01393626 and NCT01393899.

Source: Gut - May 12, 2017 Category: Gastroenterology Authors: Panes, J., Sandborn, W. J., Schreiber, S., Sands, B. E., Vermeire, S., D'Haens, G., Panaccione, R., Higgins, P. D. R., Colombel, J.-F., Feagan, B. G., Chan, G., Moscariello, M., Wang, W., Niezychowski, W., Marren, A., Healey, P., Maller, E. Tags: Open access Inflammatory bowel disease Source Type: research